Deletion of the 13q14 chromosomal region is frequent in B cell chronic lymphocytic leukemia (B-CLL) and is believed to inactivate a tumor supressor gene (TSG) next to RB1. We studied microsatellite markers spanning the 13q14 chromosomal region in 138 children with acute lymphoblastic leukemia (ALL). Allelic loss was demonstrated in six cases (4.3%). Deletion did not include RB1 in two cases. In five patients, the deleted region overlapped that described in B-CLL. A sixth patient harbored a smaller deletion, slightly more telomeric than minimal deleted regions reported in B-CLL. Apparent differences in the delineation of the minimal deleted region could be due to the fact that the putative TSG is a very large gene, with some deletions affecting only a part of it. Our present findings suggest that at least some of its exons lie within a region of less than 100 kb more telomeric that previously thought. Leukemia (2001) 15, 371-376.
Introduction
Most of the alterations that have been characterized so far in childhood acute lymphoblastic leukemia (ALL) are non-random translocations that give rise to oncogenic fusion proteins. In contrast, very few instances of inactivation of tumor suppressor genes (TSG) have been reported. However, cytogenetic and loss of heterozygosity (LOH) data point to the existence of several recurrently deleted chromosomal regions in leukemia blasts. [1] [2] [3] These chromosomal regions are likely to harbor TSG whose inactivation is involved in leukemogenesis. The 13q14 chromosomal region is known to contain the retinoblastoma susceptibility gene, RB1, which is frequently inactivated in solid tumors. 4 RB1 gene deletions are rarely seen in ALL but exceptional cases have been reported. 5, 6 More recently, a locus slightly telomeric to RB1 was shown to be the target of heterozygous or homozygous deletion in 25 to 60% cases of B cell chronic lymphocytic leukemia (B-CLL). 7, 8 This locus might be involved, although to a lesser extent, in other hematologic malignancies such as mantle cell lymphoma, 9 ,10 myeloid leukemia 11 and multiple myeloma. 12 These findings have led to the hypothesis that a second TSG exists in the 13q14 chromosomal region and is located close to RB1. However, despite strong evidence for another TSG distal to RB1, the precise location of this putative TSG is still controversial and studies aimed at identification of this gene have so far proved inconclusive.
In the present study, we assessed LOH of microsatellite markers spanning the chromosomal region 13q14 to determine the frequency of subkaryotypic deletions and to delineate the region of interest in childhood ALL. 
Patients and methods

Patients
We studied 138 children (aged 3 months to 15 years) with ALL (116 B-lineage ALL, 22 T-ALL). Six of these children were studied both at diagnosis and at marrow relapse. Children were consecutive unselected patients except that inclusion required the presence of at least 70% of blasts in marrow at the time of diagnosis. Cases of ALL with near haploid karyotype were excluded from the study. T-ALL was defined as presence of at least two of the T cell antigens CD2, CD5, and CD7. The diagnosis of B-precursor ALL was based on the expression of B cell-associated antigens (CD19
) and the lack of surface membrane immunoglobulins (Ig). B-precursor ALL displaying cytoplasmic -heavy chains (у10% of cells) but lacking surface membrane Ig were referred to as pre B-ALL. All others were designated early pre B-ALL. Karyotype studies and search for the ETV6-AML1 fusion transcript associated with t(12;21) were systematically performed at diagnosis.
Bone marrow (BM) was collected on EDTA before induction therapy and during clinical remission according to the EORTC 58 881 follow-up protocol. Mononuclear cells were separated and DNA was prepared as previously described. 13 Informed consent was obtained from the patients, their parents, or both, as appropriate.
An extensive allelotype was previously reported for 55 of these patients, the only marker in common with the present study was D13S262. 3 
Markers
Twelve simple tandem repeat (STR) markers were used that span the chromosome band 13q14. The order of these markers from centromere to telomere is according to cartography data 14 ( Figure 1 ): D13S153, D13S273, D13S272, D13S319, AFM206xf12, AFMa301wb5, D13S1269, D13S25, D13S262, D13S294, D13S288, and D13S284. Sequences were obtained from the Genome Database (http://www.gdb.org).
Identification of new microsatellite polymorphisms
Cosmids P0445, A1124, O0064 and K1028 14 were digested with SauIIIa, Southern blotted and hybridized with a CA repeat probe (Pharmacia, Uppsala, Sweden) to reveal the presence of new potentially polymorphic markers within the region. Digested bands positive for hybridization were excised from the gel, ligated in PGEM11Z, and subjected to a second hybridization screening after bacterial transformation and filter transfer. Inserts from positive clones were sequenced. Two new CA repeats named O13 and K16 were characterized. Pri- mers were designed that permitted PCR amplification of O13 (O13aF: TTAATAATTTGCCTAAGAAACG; O13m: GGATG TGTACATGATGGCAT; size of the PCR product: 104 bp) and K16 (K16aF: TACTTGTGAATAGCACAAGACGA; K16m: AGAAGTTCTGTACGCTCTTGC; size of the PCR product 127 bp). The O13 repeat is present on cosmids O0064 and A1124 while the K16 repeat is present on cosmid K1028, centromeric to marker D13S294 ( Figure 1 ).
Genotyping
Polymerase chain reaction (PCR) was carried out with a 5Ј fluorescein-labeled upstream primer as previously described. 13 PCR products were analyzed using a fluorescent automated laser DNA sequencer (ALF; Pharmacia LKB Biotechnology, Uppsala, Sweden). Electrophoresis was performed on a 6% long ranger gel (Bioprobe, Paris, France) containing 8 mol/l urea in a 0.6 × Tris-borate-EDTA buffer. Areas of the peaks corresponding to each allele were determined using the integration software Smart Manager (Pharmacia).
Allelic losses were scored as decreases in intensity of one allele relative to the other (Figures 2 and 3 ). The ratio of signal for allele A1 to allele A2 was calculated for remission and blastic samples in each patient. A ratio of remission to tumor dosage data was then calculated as:
Interpretation was always done taking into account the amount of normal cells present in each sample. With the exception of some cases in which the presence of stutter bands of contiguous alleles hampered such evaluation, samples were considered to have undergone LOH when the ratio was below the percentage of normal residual cells present in blastic samples. 13 Comparison of LOH and FISH data in previous studies indicated that, when using fluorescence detection, LOH can be reliably detected in samples containing up to 30% residual normal cells. 15, 16 Semiquantitative PCR was conducted on marker D13S25 by comparison with marker D13S284 to correct for variations in DNA dosage. The same amount of DNA from blasts and remission samples was submitted to 15, 20, 25, 30 and 35 cycles of PCR. The increase in signal intensity with the number of PCR cycles was compared between blasts and normal
Figure 2
Results of marker D13S25 analysis for patients displaying LOH. After electrophoresis of fluorescent PCR products, each allele gave rise to a major peak, the size of which depends on the number of nucleotide repeats, associated to a smaller, less intense product or 'stutter band'. Comparison of tumoral and normal allelic patterns for each patient shows allelic losses, indicated by (*).
Figure 3
Results of microsatellite analysis obtained in patient 3. For marker D13S262, loss of heterozygosity is evidenced by a reduction of allele A1 relative intensity (*) in tumor sample at diagnosis (90% of blasts) and relapse (98% of blasts). Flanking markers D13S25 and K16, and all other 13q14 markers, retained heterozygosity in tumor cells. (A1, allele 1; A2, allele 2).
Leukemia DNA after agarose electrophoresis and ethidium bromide staining.
Fluorescent in situ hybridization (FISH)
Probes used for FISH consisted of cosmids P0445, A1124, O0064, and K1028.
14 Cosmids were labeled by nick-translation with fluorescein-isothiocyanate (FITC)-dUTP (NEN) or SpectrumOrange dUTP (Vysis, Downers Grove, IL, USA). Dual-color FISH experiments were performed according to standard protocols. Briefly, 50 ng of each probe and 1 g of Cot1-DNA (BRL, Gaithersburg, MD, USA) were precipitated and resuspended in 10 l of Hybrisol VII (Oncor, Gaithersburg, MD, USA). After denaturation at 73°C for 10 min, probes and Cot1-DNA were allowed to preanneal at 37°C for 15-30 min. The probe mixture was then dropped on denatured patient cells and coverslipped. After overnight hybridization at 37°C, coverslips were removed, and slides were washed in 2 × SSC at 73°C for 5 min, rinsed in 2 × SSC/0.1% Triton X100, and counterstained with DAPI in antifade. Slides were then examined with an epifluorescence microscope (Axioplan 2, Zeiss, Jena, Germany), equipped with a cooled CCD camera (Photometrics, Tucson, AZ, USA). These cosmid probes have been previously tested on control bone marrow cells obtained from healthy bone marrow donors. For each probe, 2000 cells were evaluated, and cutoff values for deletion were determined as mean + 3 standard deviations. Cut-off values were fixed at 8%, 6%, 7% and 7% for P0445, A1124, O0064, and K1028, respectively.
Statistical analysis
Prognoses between subgroups of patients with or without 13q LOH were compared using the Fisher exact test with calculation of the 95% confidence interval of the difference in relapse rate.
Results and discussion
Frequency of 13q14 deletions in ALL
First, LOH of the 13q14 region was studied in 86 patients with ALL using microsatellite markers covering the 13q14 chromosomal band. LOH of at least one microsatellite marker was found in four patients. One patient had LOH of marker D13S262 only (Figure 3 ). Fifty-two additional patients with ALL were analyzed using markers D13S262, and D13S319 which has been proposed as a major deletion hot-spot in B-CLL. 15 Two additional cases of LOH were found. In these cases the whole panel of markers was subsequently analyzed.
Conventional cytogenetics, FISH and search for LOH have been proven to be efficient methods to pinpoint loss of chromosomal material and identify suppressor genes from their localization. However, each method has advantages and limitations. Alterations such as mitotic recombinations, or acquired monoparental isodisomies lead to LOH but remain undetected by karyotype or FISH analysis. 17 Such mechanisms have been suspected to be responsible for some cases of 13q alterations in lymphoid malignancies. 18 Moreover, small deletions are not detected by conventional cytogenetics. These reasons could explain why LOH was detected in three ALL which did not display 13q alteration on karyotype ( Table Table 1 Characteristics and outcome of patients with ALL displaying chromosome 13q abnormalities 1). On the other hand, FISH, and, on some occasions, conventional cytogenetics, can detect deletions limited to a subclone of cells, which is not the case using LOH analysis. Of the 138 patients we studied, five (3.6%) displayed a cytogenetically detectable 13q deletion ( Table 1) . LOH of the 13q14 region was observed in only two of the patients with a cytogenetically detectable 13q deletion. One explanation is that, because of in vitro selection, cytogenetics detected abnormalities that exist only in a subclone of malignant cells. This is probably the case for patient 8, whose chromosome 13 monosomy is only present in a subclone of malignant cells (Table  1 ). Another possibility is that, in some patients (eg patients 7 and 9), chromosome 13 deletions affect a different region.
A total of 138 ALL were studied (116 B-lineage ALL, 22 T-ALL) and LOH of 13q14 region was demonstrated in six ALL (4.3%). Fourty-eight additional childhood ALL were studied by FISH. Four to six of the following cosmids, spanning chromosome 13q from marker S13S319 to D13S294, were used as probes: P035, I0832, C0442, C1733, A0919, D2328, P1842, and K1028.
14 Only one case (2%) of chromosome 13q14 deletion was observed (HA-L, unpublished results). Although it is possible that 13q14 deletions restricted to subclones of blasts have been missed in some patients studied by LOH analysis, comparison of LOH and FISH results suggest that this event is not very frequent. However, as deletion might not be the only inactivating event, the frequency of alteration we found is a minimum estimate. The rather low frequency of 13q deletions we found in ALL contrasts strikingly with that reported by Liu et al. 18 Using markers D13S319 and D13S25, these authors detected a 13q14 deletion in eight out of 29 childhood ALL (28%). Although the authors did not mention this point, it seems possible that selection bias may have been involved.
Alterations of the 13q14 chromosomal region are not lineage-specific as they were found in one T-ALL, one pre-B ALL and four early pre-B ALL (Table 1) . Surprisingly, 4/6 (66.7%) patients displaying 13q14 LOH relapsed as compared with 28/132 (21.2%) patients displaying no 13q14 alteration (Table  1) . Although the number of patients with the alteration is very low, the difference in prognosis is significant (Fisher exact test, P = 0.026), and the 95% confidence interval of the difference in relapse rate is quite wide (0.071-83.8), but does not contain 0.
Delineation of the minimal deleted region
The LOH region was large in most patients. However, in two patients ( Figure 1 , Nos 2 and 3), marker D13S153, which maps within RB1, was not deleted. In one patient (No. 3), marker D13S262 was deleted while markers K16 on the telomeric side and D13S25 on the centromeric side retained heterozygosity ( Figure 3) . The same deletion in 13q14 was found in the marrow relapse sample of this patient (Figure 3) . Because of the amplification of residual normal cells always present in blastic samples, homozygous deletion can give the same amplification pattern of microsatellite markers as normal DNA. Thus, a homozygous deletion of marker D13S25, an event that has been frequently reported in B-CLL, could not be excluded in this patient. Semiquantitative PCR results indicated that two copies of marker D13S25 were still present in the leukemia blasts of patient No. 3. Using as probes cosmid P0445, which contains markers D13S25 and D13S262, cosmid A1124 which contains marker D13S262, cosmid O0064, which is located between markers D13S262 and D13S294, and cosmid K1028, which contains K16 and D13S294 at its 3Ј end (Figure 1 ), FISH analysis confirmed the presence of a mono-allelic deletion in this patient. Cosmids A1124 and O0064 showed hemizygous deletion while no deletion was observed using cosmid P0445 and K1028 ( Figure  4 ). According to the physical map established by BouygeMoreau et al, 14 the deleted region in this patient is less than 100 kb.
Loss of genetic material on chromosome 13q has been mainly reported in B-CLL (up to 60% of cases), but also in other lymphoid proliferative diseases such as mantle cell lymphoma (38-70% of cases).
9, 10 The frequency of such deletions in B-CLL has prompted many investigators to refine the region FISH analysis on leukemia cells from patient 3. Hybridization on interphase nuclei shows hemizygous deletion for cosmid O0064 while cosmid K1028 is conserved. The lower spot corresponds to the superimposition of cosmids K1028 and O0064 on the undeleted allele. The upper spot corresponds to the hybridization of cosmid K1028 only on the deleted allele.
of deletion in order to achieve positional cloning of the target gene. Brown et al 7 were the first to propose the presence of a new TSG located telomeric to RB1 and close to the D13S25 locus. Homozygous loss of D13S25 with retention of at least one RB1 allele was confirmed by several studies. 8, [18] [19] [20] [21] [22] [23] [24] [25] Construction of high-resolution physical maps of the region and mapping of additional polymorphic markers permitted further delineation of the critical region. 14, 22, 24, 26 The smallest common region of deletions reported by Lichter et al 27 is flanked by markers D13S273 and D13S272. This region overlaps with the minimal region reported by Kalachikov et al 24 but not with that of Bullrich et al 23 which is more telomeric, between markers AFM206xf12 and D13S25. Deletions that have been reported are usually very large and loss of non-contiguous loci was frequently observed in some studies 23, 24 but not in others. 21 Consequently, despite the large number of patients studied, the delineation of a minimal region of LOH is often based on a single patient. 23, 24 This might explain the disagreements between different reports concerning the region of interest. In ALL, Liu et al 18 described a minimal region of loss between markers D13S25 and D13S319. The small deleted region we found in one patient with ALL is more telomeric and is flanked by markers D13S25 and K16. As deletional areas do not include RB1 in two cases, it seems likely that RB1 is not the target of deletional events. LOH results in B-CLL are quite conflicting and a large majority of patients with B-CLL displays 13q14 deletions encompassing our region. Thus, our data suggest that the target gene in ALL could be the same as the gene deleted in B-CLL. Apparent discrepancies in the delineation of the minimal deleted region could be due to the fact that the putative tumor suppressor gene is a very large gene, with some deletions targeting only a part of it. The search for expressed sequences in the critical region led to the identification of two genes termed Leu1 and Leu2. 28 However, no evidence of their biallelic inactivation in B-CLL could be shown (29) . Our findings suggest that at least some exons of the putative TSG lie more telomeric than previously thought and should help to identify it. Sequencing of the whole genomic region is currently under way and should lead to the identification of new candidate genes.
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